CEB-01 by Cebiotex for Pleomorphic Liposarcoma: Likelihood of Approval

CEB-01 is under clinical development by Cebiotex and currently in Phase I for Pleomorphic Liposarcoma.

Surfing, camping, and deciding when to stop: Australia’s human-centric approach to dialysis

In 1972, as Congress promised dialysis and rehabilitation for all kidney failure patients in America, Australia was passing its own law to guarantee universal dialysis

August 25, 2023

Pharmalittle: We’re reading about FDA’s syphillis-drug plan, India’s manufacturer-inspection demands, and more

Rise and shine, another busy day is on the way. However, this is also shaping up as a beautiful day as well, given the clear

January 11, 2024

Abbott’s neurostimulator recall, with 73 injuries reported, deemed Class I by FDA

Dive Brief: Abbott’s recall of its Proclaim and Infinity neurostimulation systems was categorized by the Food and Drug Administration as a Class I recall. Abbott contacted

September 14, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.